Skip to main content

Invitrogen To Use BioProcessors SimCell in PD-Direct Services Offering

NEW YORK, June 20 (GenomeWeb News) - Invitrogen said today that it will add the SimCell robotic system from BioProcessors to its process development services offering.

 

Under the terms of the technology collaboration agreement, Invitrogen is installing a SimCell unit in its Grand Island, NY, facility.

 

Invitrogen's PD-Direct clients will have access to BioProcessors' high throughput simulated scale-down bioreactor tool beginning this fall. PD-Direct handles manufacturing scale-up, quality testing, and cell line optimization functions for biotechnology and pharmaceutical companies.

 

The companies will collaborate on the development of high-throughout cell culture applications for the SimCell platform and will expand microbioreactor technology for use in other areas, Invitrogen said.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.